{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:37:48Z","timestamp":1793385468432,"version":"4.5.0"},"reference-count":64,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T00:00:00Z","timestamp":1707868800000},"content-version":"unspecified","delay-in-days":13,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"crossref","award":["20H03915"],"award-info":[{"award-number":["20H03915"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>The current guidelines strongly recommend early initiation of multiple classes of cardioprotective drugs for patients with heart failure with reduced ejection fraction to improve prognosis and health status. However, evidence on the optimal sequencing of approved drugs is scarce, highlighting the importance of individualised treatment plans. Registry data indicate that only a portion of these patients can tolerate all four recommended classes, underscoring the need to establish the favoured sequence when using these drugs. Additionally, the choice between long-acting and short-acting loop diuretics in the present era remains uncertain. This is particularly relevant given the frequent use of angiotensin receptor-neprilysin inhibitor and sodium-glucose cotransporter 2 inhibitor, both of which potentiate natriuretic effects.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and analysis<\/jats:title><jats:p>In a prospective, randomised, open-label, blinded endpoint method, LAQUA-HF (Long-acting vs short-acting diuretics and neurohormonal Agents on patients\u2019 QUAlity-of-life in Heart Failure patients) will be a 2\u00d72 factorial design, with a total of 240 patients randomised to sacubitril\/valsartan versus dapagliflozin and torsemide versus furosemide in a 1:1 ratio. Most enrolment sites have participated in an ongoing observational registry for consecutive patients hospitalised for heart failure involved dedicated study coordinators, and used the same framework to enrol patients. The primary endpoint is the change in patients\u2019 health status over 6 months, defined by the Kansas City Cardiomyopathy Questionnaire. Additionally, clinical benefit at 6 months defined as a hierarchical composite endpoint will be assessed by the win ratio as the secondary endpoint.<\/jats:p><\/jats:sec><jats:sec><jats:title>Ethics and dissemination<\/jats:title><jats:p>The medical ethics committee Keio University in Japan has approved this trial. All participants provide written informed consent prior to study entry. The results of this trial will be disseminated in one main paper and additional papers on secondary endpoints and subgroup analyses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration number<\/jats:title><jats:p>UMIN000045229<\/jats:p><\/jats:sec>","DOI":"10.1136\/bmjopen-2023-076519","type":"journal-article","created":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T01:05:41Z","timestamp":1707959141000},"page":"e076519","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Rationale and protocol of the LAQUA-HF trial: a factorial randomised controlled trial evaluating the effects of neurohormonal and diuretic agents on health-status reported outcomes in heart failure patients"],"prefix":"10.1136","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8788-1186","authenticated-orcid":false,"given":"Yasuyuki","family":"Shiraishi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6347-4460","authenticated-orcid":false,"given":"Nobuhiro","family":"Ikemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuyoshi","family":"Urashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kohno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shintaro","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshikazu","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Nagatomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takenori","family":"Ikoma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiko","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Numasawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munehisa","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Takei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daihiko","family":"Hakuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Nakamaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikuko","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3779-2972","authenticated-orcid":false,"given":"Shun","family":"Kohsaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,2,14]]},"reference":[{"key":"2024021417051143000_14.2.e076519.1","doi-asserted-by":"publisher","DOI":"10.1161\/cir.0000000000001063"},{"key":"2024021417051143000_14.2.e076519.2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab368"},{"key":"2024021417051143000_14.2.e076519.3","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1002\/ehf2.13954","article-title":"Multimorbidity, guideline-directed medical therapies, and associated outcomes among hospitalized heart failure patients","volume":"9","author":"Takeuchi","year":"2022","journal-title":"ESC Heart Fail"},{"key":"2024021417051143000_14.2.e076519.4","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1016\/j.jacc.2022.03.338","article-title":"Electronic Alerts to Improve Heart Failure Therapy in Outpatient Practice: a Cluster Randomized Trial","volume":"79","author":"Ghazi","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2024021417051143000_14.2.e076519.5","first-page":"1507","article-title":"Polypharmacy and Optimization of Guideline-Directed Medical Therapy in Heart Failure","volume":"11","author":"Khan","year":"2023","journal-title":"JACC: Heart Failure"},{"key":"2024021417051143000_14.2.e076519.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.04.070"},{"key":"2024021417051143000_14.2.e076519.7","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1001\/jamacardio.2021.4585","article-title":"Evaluation of Quality of Care for US Veterans With Recent-Onset Heart Failure With Reduced Ejection Fraction","volume":"7","author":"Sandhu","year":"2022","journal-title":"JAMA Cardiol"},{"key":"2024021417051143000_14.2.e076519.8","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ijcard.2022.04.020","article-title":"Conventional medical therapy in heart failure patients eligible for the PARADIGM-HF, DAPA-HF, and SHIFT trials","volume":"359","author":"Shoji","year":"2022","journal-title":"Int J Cardiol"},{"key":"2024021417051143000_14.2.e076519.9","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1001\/jama.2022.23924","article-title":"Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure: the TRANSFORM-HF Randomized Clinical Trial","volume":"329","author":"Mentz","year":"2023","journal-title":"JAMA"},{"key":"2024021417051143000_14.2.e076519.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02076-1"},{"key":"2024021417051143000_14.2.e076519.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(19)32971-7"},{"key":"2024021417051143000_14.2.e076519.12","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/ejhf.2743","article-title":"Sequencing and titrating approach of therapy in heart failure with reduced ejection fraction following the 2021 European Society of Cardiology guidelines: an international cardiology survey","volume":"25","author":"Fauvel","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2024021417051143000_14.2.e076519.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911303"},{"key":"2024021417051143000_14.2.e076519.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022190"},{"key":"2024021417051143000_14.2.e076519.15","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/eurheartj\/ehaa968","article-title":"Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial","volume":"42","author":"Packer","year":"2021","journal-title":"Eur Heart J"},{"key":"2024021417051143000_14.2.e076519.16","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01659-1"},{"key":"2024021417051143000_14.2.e076519.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409077"},{"key":"2024021417051143000_14.2.e076519.18","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.582320"},{"key":"2024021417051143000_14.2.e076519.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2004.04.059"},{"key":"2024021417051143000_14.2.e076519.20","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(03)00765-4"},{"key":"2024021417051143000_14.2.e076519.21","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi890"},{"key":"2024021417051143000_14.2.e076519.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2005.12.072"},{"key":"2024021417051143000_14.2.e076519.23","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2005.079764"},{"key":"2024021417051143000_14.2.e076519.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.04.080"},{"key":"2024021417051143000_14.2.e076519.25","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/ejhf.1402","article-title":"Reduced loop diuretic use in patients taking sacubitril\/valsartan compared with enalapril: the PARADIGM-HF trial","volume":"21","author":"Vardeny","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2024021417051143000_14.2.e076519.26","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1161\/CIRCULATIONAHA.120.048739","article-title":"Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial","volume":"142","author":"Mordi","year":"2020","journal-title":"Circulation"},{"key":"2024021417051143000_14.2.e076519.27","unstructured":"U.S . Treatment for Heart Failure: Endpoints for Drug Development Guidance for Industry. Bethesda, MD: Food and Drug Administration, 2019."},{"key":"2024021417051143000_14.2.e076519.28","unstructured":"Food US , Administration D . Clinical outcome assessments (COA) qualification sub-missions office of cardiology H, Endocrinology, and Nephrology (OCEHM) division of cardiovascular and Nephrology (DCN). DDT COA #000084: Kansas City cardiomyopathy questionnaire (KCCQ). In: 16. 2020: Available: https:\/\/www.fda.gov\/drugs\/ddt-coa-000084-kansas-city-cardiomyopathy-questionnaire-kccq [accessed 19 May 2023]."},{"key":"2024021417051143000_14.2.e076519.29","unstructured":"Gottlieb S . Federal drug administration medical device development tool (MDDT) program. statement from FDA Commission Scott Gottlieb, MDM, on new steps to advance medical device innovation and help patients gain faster access to beneficial Technologies. In: 24. 2017: Available: https:\/\/www.fda.gov\/news-events\/press-announcements\/statement-fda-commissioner-scott-gottlieb-md-new-steps-advance-medical-device-innovation-and-help [accessed 2 Mar 2023]."},{"key":"2024021417051143000_14.2.e076519.30","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.115.001958"},{"key":"2024021417051143000_14.2.e076519.31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206286"},{"key":"2024021417051143000_14.2.e076519.32","doi-asserted-by":"crossref","unstructured":"Lewis EF , Claggett BL , McMurray JJV , et al . Health-Related Quality of Life Outcomes in PARADIGM-HF. Circ Heart Fail 2017;10:e003430. doi:10.1161\/CIRCHEARTFAILURE.116.003430","DOI":"10.1161\/CIRCHEARTFAILURE.116.003430"},{"key":"2024021417051143000_14.2.e076519.33","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jchf.2020.09.012","article-title":"Improvement of Health Status Following Initiation of Sacubitril\/Valsartan in Heart Failure and Reduced Ejection Fraction","volume":"9","author":"Pi\u00f1a","year":"2021","journal-title":"JACC Heart Fail"},{"key":"2024021417051143000_14.2.e076519.34","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.042929"},{"key":"2024021417051143000_14.2.e076519.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.09.542"},{"key":"2024021417051143000_14.2.e076519.36","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.457"},{"key":"2024021417051143000_14.2.e076519.37","doi-asserted-by":"crossref","first-page":"e411","DOI":"10.1016\/S2214-109X(20)30004-8","article-title":"Post-discharge prognosis of patients admitted to hospital for heart failure by world region, and national level of income and income disparity (REPORT-HF): a cohort study","volume":"8","author":"Tromp","year":"2020","journal-title":"Lancet Glob Health"},{"key":"2024021417051143000_14.2.e076519.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.09.072"},{"key":"2024021417051143000_14.2.e076519.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2016.09.015"},{"key":"2024021417051143000_14.2.e076519.40","doi-asserted-by":"crossref","unstructured":"Feng Y , Chen X , Schaufelberger M , et al . Patient-level comparison of heart failure patients in clinical phenotype and prognosis from China and Sweden. BMC Cardiovasc Disord 2022;22:91. doi:10.1186\/s12872-022-02540-w","DOI":"10.1186\/s12872-022-02540-w"},{"key":"2024021417051143000_14.2.e076519.41","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s00392-018-1283-6","article-title":"Outcome of hospitalised heart failure in Japan and the United Kingdom stratified by plasma N-terminal pro-B-type natriuretic peptide","volume":"107","author":"Shiraishi","year":"2018","journal-title":"Clin Res Cardiol"},{"key":"2024021417051143000_14.2.e076519.42","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw226"},{"key":"2024021417051143000_14.2.e076519.43","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(17)30196-1"},{"key":"2024021417051143000_14.2.e076519.44","doi-asserted-by":"crossref","unstructured":"Teng T-HK , Tay WT , Richards AM , et al . Socioeconomic Status and Outcomes in Heart Failure With Reduced Ejection Fraction From Asia. Circ Cardiovasc Qual Outcomes 2021;14:e006962. doi:10.1161\/CIRCOUTCOMES.120.006962","DOI":"10.1161\/CIRCOUTCOMES.120.006962"},{"key":"2024021417051143000_14.2.e076519.45","doi-asserted-by":"crossref","unstructured":"Martinez-Amezcua P , Haque W , Khera R , et al . The Upcoming Epidemic of Heart Failure in South Asia. Circ Heart Fail 2020;13:e007218. doi:10.1161\/CIRCHEARTFAILURE.120.007218","DOI":"10.1161\/CIRCHEARTFAILURE.120.007218"},{"key":"2024021417051143000_14.2.e076519.46","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s13167-011-0097-7","article-title":"Prospective care of heart failure in Japan: lessons from CHART studies","volume":"2","author":"Shiba","year":"2011","journal-title":"EPMA J"},{"key":"2024021417051143000_14.2.e076519.47","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/ejhf.788","article-title":"What proportion of patients with chronic heart failure are eligible for sacubitril-valsartan?","volume":"19","author":"Pellicori","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2024021417051143000_14.2.e076519.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.11.022"},{"key":"2024021417051143000_14.2.e076519.49","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1908655"},{"key":"2024021417051143000_14.2.e076519.50","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107038"},{"key":"2024021417051143000_14.2.e076519.51","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1103502"},{"key":"2024021417051143000_14.2.e076519.52","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11897-017-0325-0","article-title":"Registry-Based Pragmatic Trials in Heart Failure: Current Experience and Future Directions","volume":"14","author":"Lund","year":"2017","journal-title":"Curr Heart Fail Rep"},{"key":"2024021417051143000_14.2.e076519.53","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1001\/jamainternmed.2018.3931","article-title":"Estimated Costs of Pivotal Trials for Novel Therapeutic Agents Approved by the US Food and Drug Administration, 2015-2016","volume":"178","author":"Moore","year":"2018","journal-title":"JAMA Intern Med"},{"key":"2024021417051143000_14.2.e076519.54"},{"key":"2024021417051143000_14.2.e076519.55","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.cardfail.2018.07.463","article-title":"Validation and Recalibration of Seattle Heart Failure Model in Japanese Acute Heart Failure Patients","volume":"25","author":"Shiraishi","year":"2019","journal-title":"J Card Fail"},{"key":"2024021417051143000_14.2.e076519.56","doi-asserted-by":"crossref","unstructured":"Nakamaru R , Shiraishi Y , Niimi N , et al . Phenotyping of Elderly Patients With Heart Failure Focused on Noncardiac Conditions: a Latent Class Analysis From A Multicenter Registry of Patients Hospitalized With Heart Failure. J Am Heart Assoc 2023;12:e027689. doi:10.1161\/JAHA.122.027689","DOI":"10.1161\/JAHA.122.027689"},{"key":"2024021417051143000_14.2.e076519.57","doi-asserted-by":"crossref","unstructured":"Bozkurt B , Coats AJ , Tsutsui H , et al . Universal Definition and Classification of Heart Failure: a Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. J Card Fail 2021. doi:10.1016\/j.cardfail.2021.01.022","DOI":"10.1002\/ejhf.2115"},{"key":"2024021417051143000_14.2.e076519.58","doi-asserted-by":"crossref","unstructured":"Shiraishi Y , Kohsaka S , Sato N , et al . 9-Year Trend in the Management of Acute Heart Failure in Japan: a Report From the National Consortium of Acute Heart Failure Registries. J Am Heart Assoc 2018;7:e008687. doi:10.1161\/JAHA.118.008687","DOI":"10.1161\/JAHA.118.008687"},{"key":"2024021417051143000_14.2.e076519.59","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1002\/ejhf.1210","article-title":"Validation of U.S. mortality prediction models for hospitalized heart failure in the United Kingdom and Japan","volume":"20","author":"Nagai","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2024021417051143000_14.2.e076519.60","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.11.021"},{"key":"2024021417051143000_14.2.e076519.61","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.113.000359"},{"key":"2024021417051143000_14.2.e076519.62","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1161\/CIRCULATIONAHA.120.050850","article-title":"Health-Related Quality of Life and Mortality in Heart Failure: The Global Congestive Heart Failure Study of 23 000 Patients From 40 Countries","volume":"143","author":"Johansson","year":"2021","journal-title":"Circulation"},{"key":"2024021417051143000_14.2.e076519.63","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.670901"},{"key":"2024021417051143000_14.2.e076519.64","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1001\/jamacardio.2017.3983","article-title":"Association of Serial Kansas City Cardiomyopathy Questionnaire Assessments With Death and Hospitalization in Patients With Heart Failure With Preserved and Reduced Ejection Fraction: a Secondary Analysis of 2 Randomized Clinical Trials","volume":"2","author":"Pokharel","year":"2017","journal-title":"JAMA Cardiol"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2023-076519","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T01:05:59Z","timestamp":1707959159000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2023-076519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":64,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2,14]]},"published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1136\/bmjopen-2023-076519"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2023-076519","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2]]}}}